Howard Stern and TRT: How His Approach Compares to Other Public Figures

What Howard Stern Has Actually Said About TRT

Stern's disclosures about TRT have come in fragments across multiple episodes of his SiriusXM show. He has confirmed using testosterone therapy and has discussed it in the context of aging, energy, and maintaining quality of life past 65. He has not published detailed dosing or lab values.

Stern's Public Framing

Unlike some peers who frame TRT as performance optimization, Stern has discussed it as a medical intervention for age-related decline. His language on air has been clinical rather than promotional. He has referenced working with a physician and monitoring bloodwork, though specific doctor names and lab numbers remain undisclosed.

What Remains Unconfirmed

Stern has not confirmed the specific testosterone formulation he uses (cypionate, enanthate, gel, or pellet), his dose, or his injection frequency. He has not disclosed whether he uses adjunctive medications such as anastrozole for estrogen management or human chorionic gonadotropin (hCG) for fertility preservation, a common add-on in TRT protocols for men his age. Any claims about these specifics circulating online are inference, not confirmed fact.

The distinction matters clinically. The Endocrine Society's 2018 guidelines recommend testosterone therapy only for men with symptomatic androgen deficiency confirmed by at least two morning total testosterone measurements below 300 ng/dL [1]. Whether Stern met this threshold before starting therapy is unknown publicly.

The Peer Comparison Group

Several male public figures have disclosed TRT use with varying degrees of clinical detail. Comparing their approaches illustrates how differently patients and their physicians can manage the same therapy.

Joe Rogan

Rogan has been the most granular public discloser of TRT details among Stern's peer group. On multiple episodes of The Joe Rogan Experience, he has confirmed using testosterone cypionate alongside growth hormone and has discussed dosing adjustments, bloodwork results, and estrogen management with anastrozole. Rogan frames TRT as part of a broader "optimization" philosophy that includes sauna, cold plunge, and resistance training.

The key clinical difference: Rogan has described a multi-compound protocol that goes beyond isolated testosterone replacement. Adding growth hormone to TRT is not part of standard Endocrine Society or AUA guidelines for testosterone deficiency [1][2]. A 2020 meta-analysis in The Journal of Clinical Endocrinology & Metabolism found that growth hormone supplementation in eugonadal men produced modest changes in body composition but raised IGF-1 levels with uncertain long-term safety implications [3]. Rogan's protocol sits closer to what endocrinologists would classify as hormone optimization rather than replacement.

Dana White

The UFC CEO disclosed his TRT use publicly after receiving criticism for the UFC's historical allowance of TRT therapeutic use exemptions for fighters. White has spoken about testosterone therapy in the context of reversing symptoms he associated with low testosterone: fatigue, cognitive fog, and reduced motivation. He has also discussed broader health interventions including NAD+ infusions and stem cell treatments.

White's public framing is results-oriented. He has shared before-and-after photos and described measurable improvements in energy and body composition.

Dax Shepard

Shepard disclosed TRT use on his Armchair Expert podcast with a notably cautious framing. He described starting testosterone after bloodwork showed low levels and has discussed the decision in the context of his history with addiction and sobriety, expressing concern about the psychological effects of exogenous hormones.

Shepard's case is clinically interesting because substance use history can independently suppress the hypothalamic-pituitary-gonadal (HPG) axis. Chronic opioid use, for example, causes hypogonadism in up to 86% of men on long-term opioid therapy [4]. Whether Shepard's low testosterone was age-related, substance-history-related, or both has not been specified, but the distinction affects treatment duration expectations.

Sylvester Stallone

Stallone's testosterone and growth hormone use has been documented through both his own statements and a 2007 Australian customs incident in which HGH was found in his luggage. Stallone has publicly defended hormone use as anti-aging medicine. His approach sits at the far end of the dosing spectrum compared to Stern's more conservative public posture.

Stallone has stated in interviews that he believes hormone therapy is "the future" of aging. His protocol reportedly includes testosterone, growth hormone, and other peptides, placing him in a supraphysiologic category rather than standard replacement.

Clinical Evidence Behind TRT in Older Men

The evidence base for TRT in men over 60 has grown substantially since the landmark Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 790 men aged 65 and older with serum testosterone below 275 ng/dL [5].

TTrials Outcomes

The TTrials found that one year of testosterone gel therapy improved sexual function (effect size 0.45, P<0.001), physical function (modest improvement in 6-minute walk distance), and mood compared to placebo. Bone mineral density increased significantly in the spine and hip. Coronary artery plaque volume, however, increased more in the testosterone group, a finding that prompted further cardiovascular investigation [5].

The TRAVERSE Trial

The question of cardiovascular safety was addressed more definitively by the TRAVERSE trial (N=5,246), published in The New England Journal of Medicine in 2023 [6]. TRAVERSE randomized men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease to transdermal testosterone or placebo. The primary outcome of major adverse cardiovascular events (MACE) was non-inferior in the testosterone group (hazard ratio 0.96, 95% CI 0.78 to 1.17).

This matters for the Stern peer group. All of these men are in the age range (late 50s to mid-70s) where cardiovascular risk from TRT was historically a concern. TRAVERSE provides the strongest evidence to date that TRT at physiologic replacement doses does not increase MACE risk in men with or at high risk for cardiovascular disease.

Prostate Safety Data

The 2018 AUA guidelines note that TRT does not appear to increase the risk of prostate cancer based on available evidence, though PSA monitoring every 6 to 12 months remains standard practice [2]. A 2016 meta-analysis of 22 randomized controlled trials (N=2,351) published in Medicine found no significant difference in prostate cancer incidence between testosterone and placebo groups (OR 0.87, 95% CI 0.30 to 2.50) [7].

How Stern's Approach Differs From His Peers

The comparison reveals a spectrum. One end features conservative, physician-supervised, guideline-concordant testosterone replacement. The other features multi-compound hormone optimization protocols that extend well beyond what professional guidelines recommend.

Disclosure Transparency

Stern falls in the middle on disclosure. He has confirmed TRT without providing clinical specifics. The following table maps each figure along a transparency spectrum:

| Public Figure | TRT Confirmed | Dose/Formulation Disclosed | Adjunctive Compounds Disclosed | Bloodwork Shared | |---|---|---|---|---| | Howard Stern | Yes | No | No | No | | Joe Rogan | Yes | Partial | Yes (GH, anastrozole) | Partial | | Dana White | Yes | No | Yes (NAD+, stem cells) | No | | Dax Shepard | Yes | No | No | No | | Sylvester Stallone | Yes | No | Yes (GH) | No |

Protocol Complexity

Rogan and Stallone operate on the complex end, combining testosterone with growth hormone and other agents. Stern and Shepard appear, based on public statements, to use more straightforward replacement protocols. White occupies a middle ground, pairing TRT with non-hormonal interventions like NAD+ infusions.

The clinical significance: the Endocrine Society explicitly recommends against prescribing testosterone to men without confirmed deficiency and symptoms [1]. Growth hormone supplementation in non-GH-deficient adults is not recommended by the AACE 2019 guidelines and carries risks including insulin resistance, edema, carpal tunnel syndrome, and theoretical malignancy concerns [8].

Age and Risk Context

Age at TRT initiation affects the risk-benefit calculation. Total testosterone declines approximately 1 to 2% per year after age 30 according to longitudinal data from the Massachusetts Male Aging Study [9]. By age 70, a substantial fraction of men will have total testosterone levels below 300 ng/dL. The Baltimore Longitudinal Study of Aging found that the prevalence of hypogonadism (total testosterone <325 ng/dL) increased from 12% in men aged 50 to 59 to 49% in men over 80 [10].

Stern, at 72, falls squarely in the population most likely to have clinically significant testosterone deficiency. His decision to use TRT is, from a population standpoint, more aligned with guideline-recommended indications than the younger members of his peer group.

What Patients Should Take From Celebrity TRT Disclosures

Celebrity health disclosures shape public perception of medical therapies. A 2022 survey published in JAMA Network Open found that 55% of men who inquired about TRT cited media or celebrity influence as a factor in their interest [11]. This creates both opportunity and risk.

The Information Asymmetry Problem

Public figures share outcomes (more energy, better body composition, improved mood) without sharing the clinical infrastructure supporting those outcomes: serial bloodwork, physician oversight, dose titration, and monitoring for polycythemia, sleep apnea exacerbation, and hepatic effects. A listener hearing Stern or Rogan discuss TRT benefits does not hear about the hematocrit checks every 3 to 6 months or the protocol adjustments when estradiol rises above target.

Guideline-Concordant TRT Requires Monitoring

The AUA recommends the following minimum monitoring schedule for men on TRT [2]:

• Baseline: Total testosterone (two morning draws), CBC, PSA, lipid panel, metabolic panel
• 3 to 6 months: Repeat total testosterone (trough level), hematocrit, PSA
• Annually: Testosterone, hematocrit, PSA, lipid panel, DXA if indicated

Hematocrit above 54% is a trigger for dose reduction or temporary cessation. PSA increases exceeding 1.4 ng/mL per year warrant urologic referral. These thresholds apply regardless of celebrity status.

The Testosterone Formulation Question

The choice of testosterone delivery method is often overlooked in public discussions. Each formulation has distinct pharmacokinetic profiles that affect symptom control, peak-trough variability, and adherence.

Injectable Versus Topical

Testosterone cypionate (the most common injectable in the U.S.) produces peak levels 2 to 3 days post-injection and trough levels at 7 to 14 days, depending on dose and frequency. Transdermal gels (AndroGel, Testim) provide steadier levels but carry a risk of transference to household contacts, a concern the FDA addressed with a black-box warning in 2009 [12].

Subcutaneous testosterone pellets (Testopel) offer 3 to 6 month dosing intervals but require minor surgical insertion. Oral testosterone undecanoate (Jatenzo) was FDA-approved in 2019 but carries a black-box warning for blood pressure elevation [12].

Neither Stern nor most of his peers have specified their formulation. Rogan has indicated injectable use. The formulation choice matters because it affects monitoring intervals, peak-trough symptom variability, and the logistics of ongoing therapy.

The Broader Trend: TRT Prescribing in the U.S.

Stern and his peers are part of a broader prescribing trend. TRT prescriptions in the United States increased by 300% from 2001 to 2013, from approximately 1.3 million to 5.3 million prescriptions annually [13]. The trend has continued upward since, driven in part by telemedicine platforms and direct-to-consumer marketing.

A 2017 study in JAMA Internal Medicine found that approximately 25% of men starting TRT had no documented testosterone level before initiation, suggesting that a quarter of new starts may not meet guideline-recommended diagnostic criteria [14]. The Endocrine Society's 2018 guidelines were written in part to address this prescribing gap [1].

For men considering TRT after hearing about it from Stern, Rogan, or any other public figure: the starting point is two confirmed morning total testosterone levels below 300 ng/dL, accompanied by symptoms. Not a celebrity endorsement.